exon-2 (c.410C>T) leading to CTLA-4 haplo-insufficiency suggestive of ALPS-Type-V. Child was started on steroids 2 mg/kg/d and Sirolimus (titrated to levels 8-12 ng/L). He is doing well with regression of lymphadenopathy/splenomegaly and normal counts.CTLA-4 haploinsufficiency with Autoimmune Infiltration (CHAI), due to haplo-insufficiency of CTLA-4 inhibitory T-cell receptor leads to severe immune dysregulation and lymphocytic infiltration of organs including but not limited to lungs, brain and gastro-intestinal system [2]. CHAI, common in older children and young adults, has predisposition to develop lymphoma due to hyperproliferation of lymphocytes [3]. Steroids, Sirolimus and Mycophenolate mofetil are main-stay of therapy; Abatacept, competing with CD-28 inhibiting co-stimulatory signalling and T-cell activation is effective. Allogeneic stem cell transplantation is rarely necessary [4].High index of suspicion and judicious use of clinical exome sequencing help to characterize these rare disorders better.
Von Willebrand disease (VWD) Type 3 is an uncommon bleeding disorder, resulting from the near absence of Von Willebrand factor (VWF) and extremely low factor-VIII levels. It is a close differential diagnosis of hemophilia. A wide heterogeneity of VWD mutations are reported in the literature. We report a 16-year-old girl with hemarthrosis, finally diagnosed with Type 3 VWD. Clinical exome sequencing confirmed the diagnosis, revealing a homozygous mutation c.4387G>T (p. Glu1463Ter) in exon 28 of the VWF gene, a unique mutation not yet reported in the literature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.